Verscend Technologies is buying Cotiviti in a deal worth $4.9 billion, including debt. Verscend analyzes health care data, and Cotiviti audits providers to make sure payments are correct.
Why it matters: Private equity firms back both companies (Veritas Capital for Verscend and Advent International for Cotiviti), showing their desire for Cotiviti's very profitable niche industry. And that industry only exists because of the immense waste within the U.S. health care system.
Go deeper: Private equity and surprise bills.